Filtered By:
Management: Medicaid
This page shows you your search results in order of relevance. This is page number 10.
Order by Relevance | Date
Total 217 results found since Jan 2013.
Trump's Pick To Lead Health Agency Calls EpiPen Issue 'Disturbing'
U.S. President Donald Trump’s choice to lead an important health agency said on Thursday that the way pharmaceutical companies classify products as generic or branded needs to be reviewed in order to help hold down government spending, as she cited Mylan NV’s EpiPen emergency allergy treatment.
Seema Verma, Trump’s nominee to lead the Centers for Medicare and Medicaid Services (CMS), did not answer questions about whether the U.S. government should negotiate with pharmaceutical companies over drug prices.
“I think what happened with ... the EpiPen issue is very disturbing,” Verma said at her c...
Source: Healthy Living - The Huffington Post - February 17, 2017 Category: Consumer Health News Source Type: news
D.C. Week: Advocates for Medicaid Enrollees Blast Potential Cuts
(MedPage Today) -- Also: FDA panel gives the nod to Sentinel device despite questionable efficacy
Source: MedPage Today Allergy - February 25, 2017 Category: Allergy & Immunology Source Type: news
Urban Residence, Neighborhood Poverty, race/ethnicity and Asthma Morbidity Among Children in Medicaid
Among children enrolled in Medicaid, residence in an urban area is not a risk factor for prevalent asthma, but residence in urban or poor areas, and Black race/ethnicity are each independent risk factors for asthma emergency room visits and hospitalizations.
Source: Journal of Allergy and Clinical Immunology - March 6, 2017 Category: Allergy & Immunology Authors: Corinne A. Keet, Elizabeth Matsui, Meredith C. McCormack, Roger Peng Source Type: research
Mylan Recalls 81,000 EpiPens Outside U.S. After Reports Of Failure
Generic drugmaker Mylan NV has recalled about 81,000 EpiPen devices in countries outside the United States, following two reports of the life-saving allergy shot failing to work in emergencies.
In both situations, patients were able to obtain treatment through the use of an alternate EpiPen, Mylan said on Wednesday.
The recall affects devices distributed in Australia, New Zealand, Europe and Japan only, according to the company.
Mylan said it is working with the regulatory authorities, where appropriate, to inform them about the recall.
The U.S. drugmaker, which is the focus of multiple federal investigations, has come und...
Source: Healthy Living - The Huffington Post - March 24, 2017 Category: Consumer Health News Source Type: news
Mylan underpayment on EpiPen could exceed proposed settlement -study
NEW YORK (Reuters) - The amount that drugmaker Mylan NV avoided paying the U.S. government in Medicaid rebates for its EpiPen emergency allergy treatment since 2007 likely exceeds a proposed $465 million settlement the company announced in October, according to a study by private drug pricing experts published on Monday.
Source: Reuters: Health - March 27, 2017 Category: Consumer Health News Tags: healthNews Source Type: news
Urban residence, neighborhood poverty, race/ethnicity, and asthma morbidity among children on Medicaid
Although poor-urban (inner-city) areas are thought to have high asthma prevalence and morbidity, we recently found that inner cities do not have higher prevalent pediatric asthma. Whether asthma morbidity is higher in inner-city areas across the United States is not known.
Source: Journal of Allergy and Clinical Immunology - March 7, 2017 Category: Allergy & Immunology Authors: Corinne A. Keet, Elizabeth C. Matsui, Meredith C. McCormack, Roger D. Peng Source Type: research
Support for Health Law Up to 48 Percent in February
Kaiser Family Foundation poll: two - thirds of Americans feel Medicaid should continue as is today
Source: Pulmonary Medicine News - Doctors Lounge - March 15, 2017 Category: Respiratory Medicine Tags: Cardiology, Dermatology, Endocrinology, Family Medicine, Geriatrics, Gastroenterology, Gynecology, Infections, AIDS, Internal Medicine, Allergy, Critical Care, Emergency Medicine, Nephrology, Neurology, Nursing, Oncology, Ophthalmology, Orthopedics, ENT, Source Type: news
ACA ’ s Medicaid Expansion May Pose Challenges to Timely Care
Research shows benefit, but also more problems with patients getting appointments
Source: Pulmonary Medicine News - Doctors Lounge - March 9, 2017 Category: Respiratory Medicine Tags: Cardiology, Dermatology, Endocrinology, Family Medicine, Geriatrics, Gastroenterology, Gynecology, Infections, AIDS, Internal Medicine, Allergy, Emergency Medicine, Nephrology, Neurology, Nursing, Oncology, Ophthalmology, Orthopedics, ENT, Pediatrics, Pha Source Type: news
Sinus procedures in the Medicare population from 2000 to 2014: A recent balloon sinuplasty explosion
ConclusionAlthough the total number of sinus procedures increased from 2000 to 2014, the number of BSP increased at a substantially greater rate since the introduction of CPT codes for these procedures in 2011. Nationwide increases in sinus providers were driven by new providers performing balloon‐guided procedures.
Level of Evidence4. Laryngoscope, 2017
Source: The Laryngoscope - April 1, 2017 Category: ENT & OMF Authors: Nathaniel E. Calixto, Twyla Gregg ‐Jaymes, Jonathan Liang, Nancy Jiang Tags: Allergy/Rhinology Source Type: research
Outpatient Wait Times Are Longer for Medicaid Recipients
Researchers suggest lag time might be due to providers having larger caseloads
Source: The Doctors Lounge - Psychiatry - May 11, 2017 Category: Psychiatry Tags: Cardiology, Dermatology, Endocrinology, Family Medicine, Geriatrics, Gastroenterology, Gynecology, Infections, AIDS, Internal Medicine, Allergy, Nephrology, Neurology, Oncology, Ophthalmology, Orthopedics, ENT, Pediatrics, Psychiatry, Pulmonology, Rheumat Source Type: news
Report: Mylan may have overcharged US by $1.3B for EpiPen
Mylan (NSDQ:MYL) shares dipped slightly in mid-afternoon trading today after Sen. Chuck Grassley’s (R-Iowa) office released a Health and Human Services estimate claiming that taxpayers overpaid by as much as $1.27 billion for Mylan’s EpiPen device from 2006 to 2016.
The charges stem from Mylan’s decision to classify the emergency allergy auto-injector as a generic, instead of a branded product under the Medicaid Drug Rebate Program. Misclassifying the device allowed the company to pay the government a 13% rebate instead of a 23% rebate. The Centers for Medicare and Medicaid Services repeatedly warned Mylan that the...
Source: Mass Device - May 31, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Drug-Device Combinations Pharmaceuticals Wall Street Beat Centers for Medicare and Medicaid Services (CMS) Mylan Source Type: news
Mylan May Have Overcharged U.S. For EpiPen By $1.27 Billion
By Michael Erman
NEW YORK (Reuters) - The U.S. government may have overpaid drugmaker Mylan N.V. by as much as $1.27 billion between 2006 and 2016 for its EpiPen emergency allergy treatment, the Department of Health and Human Services said on Wednesday.
The amount is nearly three times a proposed settlement that the company announced in October.
The analysis on the EpiPen payments, which was conducted by the Department of Health and Human Services’ Office of Inspector General, was released by Republican Senator Chuck Grassley.
“Mylan and the Obama Administration reportedly were close to settling the overpayment...
Source: Healthy Living - The Huffington Post - June 1, 2017 Category: Consumer Health News Source Type: news
Firm urges shareholders to vote against Mylan board nominees
Shareholder advisory firm ISS issued a report today urging its clients to vote against 10 of Mylan‘s (NSDQ:MYL) board members and executive pay packages, including chief executive Heather Bresch and chairman Robert Coury.
The recommendation comes after a group of influential investors, including the New York City and State pension funds, encouraged other shareholders to vote against 6 board members and Coury.
ISS echoed the pension funds’ concerns, writing that the board mismanaged the widespread criticism around Mylan’s pricey EpiPen allergy auto-injector. The company is now the subject of numerous investigations i...
Source: Mass Device - June 12, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Drug-Device Combinations Pharmaceuticals Respiratory Wall Street Beat Mylan Source Type: news
